Puzi City

Researchers are conducting a Phase 2 trial in Taiwan to compare treatments aimed at lowering LDL cholesterol in patients who recently experienced an ischemic stroke or transient ischemic attack (TIA) and have atherosclerosis. The study focuses on patients aged 20 to 100 years with LDL-C levels of 100 mg/dL or higher within 30 days after their stroke or TIA. Participants will be randomly assigned to one of two groups: an experimental group receiving a combination of moderate-intensity statin plus ezetimibe, and a control group receiving moderate- or high-intensity statin alone (rosuvastatin or atorvastatin). Medications will be started within 2 days after randomization. During the study, researchers will monitor LDL-C levels, with the primary goal of achieving LDL-C below 70 mg/dL six months after randomization. Participants will be assessed for safety and treatment effects through regular follow-ups as part of the trial conducted at six medical institutions.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.